The success story of hemophilia care first began in the 1970s, when the availability of
plasma-derived concentrates of coagulation factor VIII (FVIII) and factor IX (FIX) provided …

Biotherapeutic proteins represent a mainstay of treatment for a multitude of conditions, for
example, autoimmune disorders, hematologic disorders, hormonal dysregulation, cancers …

The purpose of making a “biobetter” biologic is to improve on the salient characteristics of a
known biologic for which there is, minimally, clinical proof of concept or, maximally …

With the goal of emphasizing the striking advances that materialized in hemophilia care
particularly in the last 10 years, the progress of knowledge that started from the 1970s will …

Fc‐Fusion proteins represent a successful class of biopharmaceutical products, with already
13 drugs approved in the European Union and United States as well as three biosimilar …

Background Prophylactic factor replacement in patients with hemophilia B improves
outcomes but requires frequent injections. A recombinant factor IX Fc fusion protein (rFIXFc) …

First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
49447811&utm_source= google_patent&utm_medium= platform_link&utm_campaign …

Nearly 350 IgG-based therapeutics are approved for clinical use or are under development
for many diseases lacking adequate treatment options. These include molecularly …

First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
49235350&utm_source= google_patent&utm_medium= platform_link&utm_campaign …

Background Prophylaxis with either intravenous (iv) factor VIII (FVIII) or FIX is the gold
standard of care for patients with severe hemophilia. A monoclonal antibody (concizumab) …